Biogen and City Therapeutics have announced a partnership worth over $1bn to develop new RNAi therapies. The collaboration ...

Sanofi has announced that it will be acquiring Vigil Neuroscience and its investigational Alzheimer’s disease (AD) drug for ...

These groundbreaking treatments offer new hope for patients to live longer and healthier lives. But ensuring patients benefit ...

Johnson & Johnson (J&J) has announced that a US Food and Drug Administration (FDA) panel of experts has recommended Darzalex ...

Results presented at this year’s American Thoracic Society International Conference showed that the trials met their primary ...

This sounds entirely obvious but failure to translate this insight into more innovative patient support contributes to the ...

Merck & Co – known as MSD outside the US and Canada – has shared promising results from a late-stage study of its anti-PD-1 ...

Join us on an adventure Alex Legg is one of 15 speakers at Adventures In Pharma on 1 July in London. Join him there to ...

Bristol Myers Squibb (BMS) has announced that its PD-1 immune checkpoint inhibitor Opdivo (nivolumab) has been approved by ...

Science communication, together with creativity, ensures that information is both accurate and accessible. In order to ...

Olaparib tablets, marketed under the brand name Lynparza, are already available on the NHS for certain breast cancer ...

The agreement between BioNTech’s subsidiary BioNTech UK and the UK government is focused on accelerating clinical trials for ...